Xencor Inc. (XNCR) 15.47 $XNCR
Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 12, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2014 financial results after the market closes on Thursday, February 19, 2015. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 15.47 (-0.22)
Xencor to Webcast Presentations at Two Upcoming Conferences in February
PR Newswire - Thu Feb 05, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today announced that it will webcast presentations by Bassil Dahiyat, Ph.D., president and chief executive officer, at two upcoming conferences in February:
XNCR: 15.47 (-0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDWR: 20.85 (+0.42), ESIO: 6.50 (+0.02), MCEP: 6.29 (+0.12), OTEX: 61.19 (+0.99), SSRI: 6.26 (+0.13), OTC.TO: 76.24 (+1.06), AREX: 8.15 (+0.27), SSO.TO: 7.81 (+0.16), EZPW: 9.96 (-0.29), WLB: 28.91 (+0.29), ATTU: 9.93 (+0.05), MITL: 10.33 (+0.12), XNCR: 15.47 (-0.22), FTNT: 33.23 (+0.25)
Xencor up on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:25AM CST
XNCR: 15.47 (-0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers
PR Newswire - Thu Jan 29, 6:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. A dose limiting toxicity of transient, asymptomatic thrombocytopenia was observed at the 3.0 mg/kg dose. Two subjects with high pre-dose IgE levels (above 400 IU/mL) were treated with XmAb7195, one each at 0.75 mg/kg and 3.0 mg/kg doses, and both had reduction of free IgE levels to below the limit of detection lasting for at least one week. XmAb7195 is an anti-IgE monoclonal antibody containing Xencor's proprietary XmAb Immune Inhibitor Fc domain that targets FcRIIb, which results in rapid clearance of free and total IgE and inhibition of the function of IgE expressing B cells.
XNCR: 15.47 (-0.22)
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis
PR Newswire - Thu Jan 29, 6:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported top-line results from a Phase 1b/2a study for XmAb®5871. In addition to the study's primary objective of characterizing safety and tolerability, the data showed promising activity in patients with rheumatoid arthritis (RA), including multiple DAS28-CRP remissions and ACR50 and ACR70 responses. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary XmAb immune inhibitor Fc domain that targets FcRIIb to inhibit B-cell function.
XNCR: 15.47 (-0.22)
Can The Uptrend Continue for Xencor (XNCR)?
Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 12, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2014 financial results after the market closes on Thursday, February 19, 2015. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
XNCR: 15.47 (-0.22)
Xencor to Webcast Presentations at Two Upcoming Conferences in February
PR Newswire - Thu Feb 05, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today announced that it will webcast presentations by Bassil Dahiyat, Ph.D., president and chief executive officer, at two upcoming conferences in February:
XNCR: 15.47 (-0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), PSTI: 2.91 (+0.01), APPY: 0.45 (-0.01), NVC.TO: 11.27 (-0.23), GEVO: 0.23 (+0.03), PSTB: 6.94 (+0.04), OVLY: 10.65 (-0.05), PFMT: 6.02 (-0.02), BWINB: 23.41 (+0.01), AMIC: 10.75 (-0.10), APRI: 1.84 (-0.08), BWINA: 23.45 (-0.79), INOD: 2.78 (-0.02), XNCR: 15.47 (-0.22), FBSS: 17.59 (-0.11), NVCN: 9.08 (-0.17)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 29, 5:14PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RDWR: 20.85 (+0.42), ESIO: 6.50 (+0.02), MCEP: 6.29 (+0.12), OTEX: 61.19 (+0.99), SSRI: 6.26 (+0.13), OTC.TO: 76.24 (+1.06), AREX: 8.15 (+0.27), SSO.TO: 7.81 (+0.16), EZPW: 9.96 (-0.29), WLB: 28.91 (+0.29), ATTU: 9.93 (+0.05), MITL: 10.33 (+0.12), XNCR: 15.47 (-0.22), FTNT: 33.23 (+0.25)
Xencor up on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:25AM CST
XNCR: 15.47 (-0.22)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 8:12AM CST
CRMD: 3.27 (+0.02), FRO: 2.96 (+0.07), PSTI: 2.91 (+0.01), SILC: 46.99 (+0.90), VVUS: 2.68 (+0.13), NBG: 1.61 (+0.18), APPY: 0.45 (-0.01), CLB: 112.18 (+3.65), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), COH: 39.85 (+0.64), QCOM: 70.88 (+0.49), IRE: 14.54 (+0.81), VGGL: 1.77 (-0.08), KATE: 33.89 (+0.05), XNCR: 15.47 (-0.22), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), BABA: 89.05 (+1.95)
Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers
PR Newswire - Thu Jan 29, 6:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. A dose limiting toxicity of transient, asymptomatic thrombocytopenia was observed at the 3.0 mg/kg dose. Two subjects with high pre-dose IgE levels (above 400 IU/mL) were treated with XmAb7195, one each at 0.75 mg/kg and 3.0 mg/kg doses, and both had reduction of free IgE levels to below the limit of detection lasting for at least one week. XmAb7195 is an anti-IgE monoclonal antibody containing Xencor's proprietary XmAb Immune Inhibitor Fc domain that targets FcRIIb, which results in rapid clearance of free and total IgE and inhibition of the function of IgE expressing B cells.
XNCR: 15.47 (-0.22)
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis
PR Newswire - Thu Jan 29, 6:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported top-line results from a Phase 1b/2a study for XmAb®5871. In addition to the study's primary objective of characterizing safety and tolerability, the data showed promising activity in patients with rheumatoid arthritis (RA), including multiple DAS28-CRP remissions and ACR50 and ACR70 responses. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary XmAb immune inhibitor Fc domain that targets FcRIIb to inhibit B-cell function.
XNCR: 15.47 (-0.22)
Can The Uptrend Continue for Xencor (XNCR)?
